Shnayder, N.A.,
Novitsky, M.A.,
Neznanov, N.G.,
Limankin, O.V.,
Asadullin, A.R.,
Petrov, A.V.,
Dmitrenko, D.V.,
Narodova, E.A.,
Popenko, N.V.,
Nasyrova, R.F. (2022) of the pathophysiology and/or
genetic predictors of these mental disorders. The aim of this study was to review
Vaiman, E.E.,
Shnayder, N.A.,
Zhuravlev, N.M.,
Petrova, M.M.,
Asadullin, A.R.,
Al-Zamil, M.,
Garganeeva, N.R.,
Shipulin, G.A.,
Cumming, G.,
Nasyrova, R.F. (2022) , and monotherapy, etc.) and non-modifying factors (
genetic predisposition, gender,
age, etc.). The
geneticПРОБЛЕМЫ И ДОСТИЖЕНИЯ В ИЗУЧЕНИИ КЛИНИКО-ГЕНЕТИЧЕСКИХ АСПЕКТОВ МУКОВИСЦИДОЗААЮПОВА, Г.Р.,
МИННИАХМЕТОВ, И.Р.,
ХУСАИНОВА, Р.И.,
AYUPOVA, G.R.,
MINNIAKHMETOV, I.R.,
KHUSAINOVA, R.I. (2022) PROBLEMS AND ACHIEVEMENTS IN THE STUDY OF CLINICAL AND
GENETIC ASPECTS OF CYSTIC FIBROSIS
Tyurin, Anton,
Merkuryeva, Elena,
Zaripova, Aliya,
Markova, Tatyana,
Nagornova, Tatyana,
Dantsev, Ilya,
Nadyrshina, Dina,
Zakharova, Ekaterina,
Khusainova, Rita (2022) , a clinical and
genetic analysis of 12 cases with
molecularly confirmed OI type V from 12 unrelated
Balkhiyarova, Z.,
Luciano, R.,
Kaakinen, M.,
Ulrich, A.,
Shmeliov, A.,
Bianchi, M.,
Chioma, L.,
Dallapiccola, B.,
Prokopenko, I.,
Manco, M. (2022) part of the
genetic background. We aimed to test if weighted
genetic risk scores (GRSs) for T2D
KHABIBOV, M.,
GARIFULLIN, A.,
KHAMITOV, F.,
KHALIKOVA, L.,
BOUMBER, Y.,
KHADDOUR, K.,
FERNANDEZ, M.,
KUZNETSOVA, N.,
KIT, O.,
KHARIN, L. (2022) and is associated with a poor
clinical prognosis. Despite the progress in the understanding of the
molecular major challenge in front of cellular therapy advancement. Many factors, ranging from
genetic